小児てんかん患者におけるフェノバルビタールの見かけのクリアランスに与える年齢及び併用薬の影響

概要

論文の詳細を見る
The effects of age and apparent clearance (ACL) of phenobarbital (PB) concurrently administered as anticonvulsant(s) were studied in 651 epileptic children ranged with age from 2 months to 16.5 years old. ACL was calculated from the following equation; ACL=Dose (mg/kg/d)・F (bioavailavility of PB)/C (serum level of PB)・τ (dosing interval). F was assumed to be 1.0 and 0.8 for elixir and powder forms of PB, respectively. ACL of PB was significantly (p<0.05) correlated with age (r=0.590-0.741) in either patients taking PB alone or taking PB with other anticonvulsant(s). ACL of PB decreased with an increase in the age of patients. Mean ACL of PB in patients taking PB with sodium valproate or with more than two other anticonvulsants was significantly (p<0.05) smaller than that of patients taking PB alone, independent of groups subdivided with age. Neither phenytoin nor carbamazepine altered ACL of PB significantly. The serum level of PB should be monitored closely in pediatric patients taking PB with sodium valproate or more than two other anticonvulsants.
公益社団法人日本薬学会の論文
1988-11-25